Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - Cardiff Oncology, Inc.trov-063018exhibit311.htm
EX-4.1 - EXHIBIT 4.1 - Cardiff Oncology, Inc.trov-0630x18exhibit41.htm
10-Q - 10-Q - Cardiff Oncology, Inc.trov-063018x10q.htm


Exhibit 32.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Trovagene, Inc. (the “Company”) on Form 10-Q for the three months ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Adams, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1)                            The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)                            The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
August 3, 2018
/s/ Thomas Adams
 
Thomas Adams
 
Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)